Panavance Therapeutics to Participate at the Virtual Investor Innovations in Oncology Spotlight Event

Panavance Therapeutics

BERWYN, PAPanavance Therapeutics Inc. announced that Greg Bosch, Chairman and CEO of Panavance Therapeutics along with other members of the Panavance Leadership Team will participate in the Virtual Investor Innovations in Oncology Spotlight Event today, December 7, 2022, at 2:00 PM ET.

As part of the virtual roundtable event, the Company will discuss its lead program, GP-2250, a tumor cell-selective and broadly active small molecule with a unique mechanism of action designed to disrupt energy metabolism, resulting in cancer cell death. GP-2250 is currently in a Phase 1 clinical trial with plans to initiate registration-directed trials in both pancreatic and ovarian cancers in late 2023 / early 2024.

In addition to the moderated portion of the event, investors and interested parties will have the opportunity to submit questions. The Company will answer as many questions as possible during the event.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News.

Thanks for visiting! Looking for some Chester County pride? We got you covered! Shop our MyChesCo store and show your love for Chester County, Pennsylvania. We got shirts, hats, and more – all with a unique ChesCo flair. Plus, proceeds from each purchase helps support our mission of bringing reliable information and resources to the people of Chester County.

READ:  Compass Mark to Host Community Addiction Conference